{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:12Z","timestamp":1790474112434,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"DOI":"10.1038\/emm.2016.131","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T08:02:13Z","timestamp":1484899333000},"page":"e286-e286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation"],"prefix":"10.1038","volume":"49","author":[{"given":"Mark Borris D","family":"Aldonza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"BFemm2016131_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570\u2013575.","journal-title":"Nature"},{"key":"BFemm2016131_CR2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature15736","volume":"528","author":"Cancer Cell Line Encyclopedia Consortium and The Genomics of Drug Sensitivity in Cancer Consortium","year":"2015","unstructured":"Cancer Cell Line Encyclopedia Consortium and The Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. Nature 2015; 528: 84\u201387.","journal-title":"Nature"},{"key":"BFemm2016131_CR3","doi-asserted-by":"publisher","first-page":"re6","DOI":"10.1126\/scisignal.2004652","volume":"6","author":"MJ Niederst","year":"2013","unstructured":"Niederst MJ, Engelman JA . Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013; 6: re6.","journal-title":"Sci Signal"},{"key":"BFemm2016131_CR4","doi-asserted-by":"publisher","first-page":"229ra43","DOI":"10.1126\/scitranslmed.3007965","volume":"6","author":"LM Zasadil","year":"2014","unstructured":"Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegragation on multipolar spindles. Sci Transl Med 2014; 6: 229ra43.","journal-title":"Sci Transl Med"},{"key":"BFemm2016131_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nature11448","volume":"490","author":"MS Jin","year":"2012","unstructured":"Jin MS, Oldham ML, Zhang Q, Chen J . Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012; 490: 566\u2013569.","journal-title":"Nature"},{"key":"BFemm2016131_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE . Multidrug resistance in cancer: role of ATP-dependent transpoters. Nat Rev Cancer 2002; 2: 48\u201358.","journal-title":"Nat Rev Cancer"},{"key":"BFemm2016131_CR7","doi-asserted-by":"publisher","first-page":"11737","DOI":"10.1073\/pnas.191388598","volume":"98","author":"A Goncalves","year":"2001","unstructured":"Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad USA 2001; 98: 11737\u201311742.","journal-title":"Proc Natl Acad USA"},{"key":"BFemm2016131_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/15680096113139990076","volume":"13","author":"Z Binkhathlan","year":"2012","unstructured":"Binkhathlan Z, Lavasanifar A . P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 2012; 13: 326\u2013346.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFemm2016131_CR9","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"H Pelicano","year":"2006","unstructured":"Pelicano H, Martin DS, Xu RH, Huang P . Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633\u20134646.","journal-title":"Oncogene"},{"key":"BFemm2016131_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind J-F . Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 2013; 12: 152.","journal-title":"Mol Cancer"},{"key":"BFemm2016131_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1365-2443.2012.01629.x","volume":"17","author":"A Nakano","year":"2012","unstructured":"Nakano A, Takashima S . LKB1 and AMP-activated protein kinase: regulators of cell polarity. Genes Cells 2012; 17: 737\u2013747.","journal-title":"Genes Cells"},{"key":"BFemm2016131_CR12","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1158\/0008-5472.CAN-07-0325","volume":"67","author":"AS Lee","year":"2007","unstructured":"Lee AS . GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007; 67: 3496\u20133499.","journal-title":"Cancer Res"},{"key":"BFemm2016131_CR13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646\u2013674.","journal-title":"Cell"},{"key":"BFemm2016131_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/1535-7163.MCT-07-0397","volume":"7","author":"RC-Y Hui","year":"2008","unstructured":"Hui RC-Y, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 2008; 7: 670\u2013678.","journal-title":"Mol Cancer Ther"},{"key":"BFemm2016131_CR15","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.1128\/MCB.01265-07","volume":"28","author":"RC-Y Hui","year":"2008","unstructured":"Hui RC-Y, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez de Mattos S et al. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase\/Akt activity in drug-resistant leukemic cell through induction of PIK3CA expression. Mol Cell Biol 2008; 28: 5886\u20135898.","journal-title":"Mol Cell Biol"},{"key":"BFemm2016131_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s11684-012-0228-0","volume":"6","author":"F Zhao","year":"2012","unstructured":"Zhao F, Lam EW . Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Front Med 2012; 6: 376\u2013380.","journal-title":"Front Med"},{"key":"BFemm2016131_CR17","doi-asserted-by":"publisher","first-page":"7410","DOI":"10.1038\/sj.onc.1209086","volume":"24","author":"EL Greer","year":"2005","unstructured":"Greer EL, Brunet A . FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410\u20137425.","journal-title":"Oncogene"},{"key":"BFemm2016131_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/156800909788166547","volume":"9","author":"TR Wilson","year":"2009","unstructured":"Wilson TR, Johnston PG, Longley DB . Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 2009; 9: 307\u2013319.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFemm2016131_CR19","doi-asserted-by":"publisher","first-page":"10146","DOI":"10.18632\/oncotarget.3380","volume":"6","author":"SY Bae","year":"2015","unstructured":"Bae SY, Hong JY, Lee HJ, Park HJ, Lee SK . Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer. Oncotarget 2015; 6: 10146\u201310160.","journal-title":"Oncotarget"},{"key":"BFemm2016131_CR20","doi-asserted-by":"publisher","first-page":"e0127841","DOI":"10.1371\/journal.pone.0127841","volume":"10","author":"MB Aldonza","year":"2015","unstructured":"Aldonza MB, Hong JY, Bae SY, Song J, Kim WK, Oh J et al. Suppression of MAPK signaling and reversal of mTOR-dependent MDR1-associated multidrug resistance by 21\u03b1-methylmelianodiol in lung cancer cells. PLoS ONE 2015; 10: e0127841.","journal-title":"PLoS ONE"},{"key":"BFemm2016131_CR21","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.fct.2011.11.008","volume":"50","author":"EH Kim","year":"2012","unstructured":"Kim EH, Min HY, Chung HJ, Song J, Park HJ, Kim S et al. Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. Food Chem Toxicol 2012; 50: 1060\u20131065.","journal-title":"Food Chem Toxicol"},{"key":"BFemm2016131_CR22","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1038\/cddis.2013.3","volume":"4","author":"H Luo","year":"2013","unstructured":"Luo H, Yang Y, Duan J, Wu P, Jiang Q, Xu C . PTEN-regulated AKT\/FoxO3a\/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis 2013; 4: e481.","journal-title":"Cell Death Dis"},{"key":"BFemm2016131_CR23","doi-asserted-by":"publisher","first-page":"e0126763","DOI":"10.1371\/journal.pone.0126763","volume":"10","author":"MD Shastri","year":"2012","unstructured":"Shastri MD, Stewart N, Horne J, Peterson GM, Gueven N, Sohal SS et al. In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin. PLoS ONE 2012; 10: e0126763.","journal-title":"PLoS ONE"},{"key":"BFemm2016131_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ymeth.2007.11.008","volume":"44","author":"Z Darzynkiewicz","year":"2008","unstructured":"Darzynkiewicz Z, Galkowski D, Zhao H . Analysis of apoptosis by cytometry using TUNEL assay. Methods 2008; 44: 250\u2013254.","journal-title":"Methods"},{"key":"BFemm2016131_CR25","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1073\/pnas.0813414106","volume":"106","author":"KJ McManus","year":"2009","unstructured":"McManus KJ, Barrett IJ, Nouhi Y, Hieter P . Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci USA 2009; 106: 3276\u20133281.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFemm2016131_CR26","first-page":"301","volume":"281","author":"P Pozarowski","year":"2004","unstructured":"Pozarowski P, Darzynkiewicz Z . Analysis of cell cycle by flow cytometry. Methods Mol Biol 2004; 281: 301\u2013311.","journal-title":"Methods Mol Biol"},{"key":"BFemm2016131_CR27","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1161\/CIRCULATIONAHA.106.681700","volume":"115","author":"S Horke","year":"2007","unstructured":"Horke S, Witte I, Wilgenbus P, Kruger M, Strand D, Forstermann U . Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007; 115: 2055\u20132064.","journal-title":"Circulation"},{"key":"BFemm2016131_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.bbapap.2014.11.002","volume":"1854","author":"SS Na","year":"2015","unstructured":"Na SS, Aldonza MB, Sung HJ, Kim YI, Son YS, Cho S et al. Stanniocalcin-2 (STC2): a potential lung cancer biomarker promotes lung cancer metastasis and progression. Biochim Biophys Acta 2015; 1854: 668\u2013676.","journal-title":"Biochim Biophys Acta"},{"key":"BFemm2016131_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1074\/mcp.M113.028621","volume":"13","author":"JM Ahn","year":"2014","unstructured":"Ahn JM, Sung HJ, Yoon YH, Kim BG, Yang WS, Lee C et al. Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol Cell Proteomics 2014; 13: 30\u201348.","journal-title":"Mol Cell Proteomics"},{"key":"BFemm2016131_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501: 346\u2013354.","journal-title":"Nature"},{"key":"BFemm2016131_CR31","doi-asserted-by":"publisher","first-page":"34395","DOI":"10.18632\/oncotarget.9118","volume":"7","author":"MBD Aldonza","year":"2016","unstructured":"Aldonza MBD, Hong JY, Alinsug MV, Song J, Lee SK . Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation. Oncotarget 2016; 7: 34395\u201334419.","journal-title":"Oncotarget"},{"key":"BFemm2016131_CR32","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2890","volume":"18","author":"Y Sun","year":"2012","unstructured":"Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012; 18: 1359\u20131368.","journal-title":"Nat Med"},{"key":"BFemm2016131_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J . Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014; 26: 207\u2013221.","journal-title":"Cancer Cell"},{"key":"BFemm2016131_CR34","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/jcb.24464","volume":"114","author":"JJ Kim","year":"2013","unstructured":"Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B et al. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem 2013; 114: 1286\u20131293.","journal-title":"J Cell Biochem"},{"key":"BFemm2016131_CR35","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1021\/pr5012894","volume":"14","author":"NW Bateman","year":"2015","unstructured":"Bateman NW, Jaworski E, Ao W, Wang G, Litzi T, Dubil E et al. Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. J Proteome Res 2015; 14: 1900\u20131910.","journal-title":"J Proteome Res"},{"key":"BFemm2016131_CR36","doi-asserted-by":"publisher","first-page":"re2","DOI":"10.1126\/scisignal.2005326","volume":"7","author":"J Aramburu","year":"2014","unstructured":"Aramburu J, Ortells MC, Tejedor S, Buxade M, Lopez-Rodriguez C . Transcriptional regulation of the stress response by mTOR. Sci Signal 2014; 7: re2.","journal-title":"Sci Signal"},{"key":"BFemm2016131_CR37","doi-asserted-by":"publisher","first-page":"ra19","DOI":"10.1126\/scisignal.2001556","volume":"4","author":"S Pyndiah","year":"2011","unstructured":"Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D . c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 2011; 4: ra19.","journal-title":"Sci Signal"},{"key":"BFemm2016131_CR38","doi-asserted-by":"publisher","first-page":"171ra17","DOI":"10.1126\/scitranslmed.3004828","volume":"5","author":"JE Allen","year":"2013","unstructured":"Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5: 171ra17.","journal-title":"Sci Transl Med"},{"key":"BFemm2016131_CR39","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.4161\/cc.7.20.6920","volume":"7","author":"AR Gomes","year":"2008","unstructured":"Gomes AR, Brosens JJ, Lam EW-F . Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008; 7: 3133\u20133135.","journal-title":"Cell Cycle"},{"key":"BFemm2016131_CR40","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13058-014-0482-y","volume":"16","author":"R Hill","year":"2014","unstructured":"Hill R, Kalathur RKR, Callejas S, Colaco L, Brandao R, Serelde B et al. A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res 2014; 16: 482.","journal-title":"Breast Cancer Res"},{"key":"BFemm2016131_CR41","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1158\/0008-5472.CAN-12-3767","volume":"73","author":"EE Santo","year":"2013","unstructured":"Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM . FOXO3a is a major target of inactivation by PI3K\/AKT signaling in aggressive neuroblastoma. Cancer Res 2013; 73: 2189\u20132198.","journal-title":"Cancer Res"},{"key":"BFemm2016131_CR42","first-page":"870","volume":"48","author":"RC Lyon","year":"1988","unstructured":"Lyon RC, Cohen JS, Faustino PJ, Megnin F, Myers CE . Glucose-metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res 1988; 48: 870\u2013877.","journal-title":"Cancer Res"},{"key":"BFemm2016131_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.freeradbiomed.2012.05.006","volume":"53","author":"C Riganti","year":"2012","unstructured":"Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D . The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 2012; 53: 421\u2013436.","journal-title":"Free Radic Biol Med"},{"key":"BFemm2016131_CR44","doi-asserted-by":"publisher","first-page":"15960","DOI":"10.1074\/jbc.M110.121871","volume":"285","author":"S Khatri","year":"2010","unstructured":"Khatri S, Yepiskoposyan H, Gallo CA, Tandon P, Plas DR . FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. J Biol Chem 2010; 285: 15960\u201315965.","journal-title":"J Biol Chem"},{"key":"BFemm2016131_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1023\/A:1009697908332","volume":"5","author":"KH Moley","year":"2000","unstructured":"Moley KH, Mueckler MM . Glucose transport and apoptosis. Apoptosis 2000; 5: 99\u2013105.","journal-title":"Apoptosis"},{"key":"BFemm2016131_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ncb3094","volume":"17","author":"MY Fong","year":"2015","unstructured":"Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 2015; 17: 183\u2013194.","journal-title":"Nat Cell Biol"},{"key":"BFemm2016131_CR47","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1038\/cddis.2013.60","volume":"4","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Butler EB, Tan M . Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532.","journal-title":"Cell Death Dis"},{"key":"BFemm2016131_CR48","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nature11706","volume":"491","author":"A Schulze","year":"2012","unstructured":"Schulze A, Harris AL . How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012; 491: 364\u2013373.","journal-title":"Nature"},{"key":"BFemm2016131_CR49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/cdd.2013.131","volume":"21","author":"PP Liu","year":"2014","unstructured":"Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ 2014; 21: 124\u2013135.","journal-title":"Cell Death Differ"},{"key":"BFemm2016131_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . A rapid and simple method for measuring thymocyte apoptosis by propium iodide staining and cytometry. J Immunol Methods 1991; 139: 271\u2013279.","journal-title":"J Immunol Methods"},{"key":"BFemm2016131_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0091-679X(08)61924-X","volume":"46","author":"PJ Fraker","year":"1995","unstructured":"Fraker PJ, King LE, Lill-Elghanian D, Telford WG . Quantification of apoptotic events in pure and heterogenous populations of cells using the flow cytometer. Methods Cell Biol 1995; 46: 57\u201376.","journal-title":"Methods Cell Biol"},{"key":"BFemm2016131_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","volume":"56","author":"MM Gottesman","year":"2016","unstructured":"Gottesman MM, Lavi O, Hall MD, Gillet JP . Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol 2016; 56: 85\u2013102.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFemm2016131_CR53","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/msb.2012.25","volume":"8","author":"K Komurov","year":"2012","unstructured":"Komurov K, Tseng JT, Muller M, Seviour EG, Moss TG, Yang L et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 2012; 8: 596.","journal-title":"Mol Syst Biol"},{"key":"BFemm2016131_CR54","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature14336","volume":"520","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 2015; 520: 368\u2013372.","journal-title":"Nature"},{"key":"BFemm2016131_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","volume":"17","author":"B Faubert","year":"2013","unstructured":"Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013; 17: 113\u2013124.","journal-title":"Cell Metab"},{"key":"BFemm2016131_CR56","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.bcp.2006.03.005","volume":"71","author":"TD King","year":"2006","unstructured":"King TD, Song L, Jope RS . AMP-activated kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase-kinase-3. Biochem Pharmacol 2006; 71: 1637\u20131647.","journal-title":"Biochem Pharmacol"},{"key":"BFemm2016131_CR57","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2676","volume":"9","author":"DB Shackelford","year":"2009","unstructured":"Shackelford DB, Shaw RJ . The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563\u2013575.","journal-title":"Nat Rev Cancer"},{"key":"BFemm2016131_CR58","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/cr.2012.108","volume":"22","author":"F Kottakis","year":"2012","unstructured":"Kottakis F, Bardeesy N . LKB1-AMPK axis revisited. Cell Res 2012; 22: 1617\u20131620.","journal-title":"Cell Res"},{"key":"BFemm2016131_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/0008-5472.CAN-11-1674","volume":"72","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res 2012; 72: 304\u2013314.","journal-title":"Cancer Res"},{"key":"BFemm2016131_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/0008-5472.CAN-03-3294","volume":"64","author":"G Maschek","year":"2004","unstructured":"Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31\u201334.","journal-title":"Cancer Res"},{"key":"BFemm2016131_CR61","doi-asserted-by":"publisher","first-page":"7406","DOI":"10.1158\/1078-0432.CCR-06-1886","volume":"12","author":"A Patnaik","year":"2006","unstructured":"Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA et al. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res 2006; 12: 7406\u20137413.","journal-title":"Clin Cancer Res"},{"key":"BFemm2016131_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01243894-200602000-00007","volume":"1","author":"YM Chen","year":"2006","unstructured":"Chen YM, Perng RP, Tsai CM, Whang-Peng J . A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-na\u00efve inoperable non-small cell lung cancer in the elderly. J Thorac Oncol 2006; 1: 141\u2013145.","journal-title":"J Thorac Oncol"},{"key":"BFemm2016131_CR63","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2002.08.080","volume":"20","author":"GK Schwartz","year":"2002","unstructured":"Schwartz GK, O\u2019Reilly E, Ilson D, Saltz L, Sharma S, Tong W et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002; 20: 2157\u20132170.","journal-title":"J Clin Oncol"},{"key":"BFemm2016131_CR64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","volume":"28","author":"SS Ramalingam","year":"2010","unstructured":"Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 56\u201362.","journal-title":"J Clin Oncol"},{"key":"BFemm2016131_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/01.COT.0000291637.65991.af","volume":"25","author":"RS Tuma","year":"2003","unstructured":"Tuma RS . Taxol\u2019s journey from discovery to use: lessons and updates. Oncol Times 2003; 25: 52\u201357.","journal-title":"Oncol Times"},{"key":"BFemm2016131_CR66","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA . How taxol\/paclitaxel kills cancer cells. Mol Biol Cell 2014; 25: 2677\u20132681.","journal-title":"Mol Biol Cell"},{"key":"BFemm2016131_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fonc.2014.00040","volume":"4","author":"M McDermott","year":"2014","unstructured":"McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol 2014; 4: 40.","journal-title":"Front Oncol"}],"container-title":["Experimental & Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/emm2016131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/emm2016131","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/emm2016131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T15:37:41Z","timestamp":1671723461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/emm2016131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1]]}},"alternative-id":["BFemm2016131"],"URL":"https:\/\/doi.org\/10.1038\/emm.2016.131","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]},"assertion":[{"value":"2 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}